HIV 1 RNA, Quantitative PCR, W/Reflex To Integrase Genotype
Test Summary
This test is intended for use in conjunction with clinical presentation and other laboratory markers of disease progress for the clinical management of HIV-1 infected patients. The test can be used to assess patient prognosis by measuring the baseline HIV-1 RNA level or to monitor the effects of antiretroviral therapy by measuring changes in EDTA plasma HIV-1 RNA levels during the course of antiretroviral treatment. The emergence of integrase drug resistance mutations has been observed in vitro and in patients experiencing virologic failure on Raltegravir in clinical trials. Twenty three percent of patients receiving Raltegravir in a clinical trial experience virologic failure at 48 weeks and genotypic analysis detected raltegravir associated resistance mutations in 68% of virologic failures. This assay amplifies and sequences the HIV-1 integrase gene and reports mutations at positions associated with integrase inhibitor drug resistance.
Aliases
- N/A
Specimen Collection
Special Instructions
Preferred Specimen
Minimum Volume
Instructions
Patient Preparation
Storage
Transport Temperature
Specimen Stability
- Room temperature: Unacceptable
- Refrigerated: 6 days
- Frozen: 42 days
Limitations
Other Acceptable Specimens
Unacceptable Specimens
Order Code
EPIC (Premier) Code
Includes
CPT Code
- 87536
Billing Code
- 670075
CPT Statement
Methodology
FDA Status
Physician Attestation of Informed Consent
Testing Laboratory
33608 Ortega Highway
San Juan Capistrano CA, 92675
Department
Reference Range
Setup Schedule / Expected Turnaround Time
Specimen Collection
Special Instructions
Preferred Specimen
Minimum Volume
Instructions
Patient Preparation
Storage
Transport Temperature
Specimen Stability
- Room temperature: Unacceptable
- Refrigerated: 6 days
- Frozen: 42 days